Linked Life Data

2576202

Source:http://linkedlifedata.com/resource/pubmed/id/2576202

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11A
pubmed:dateCreated
1990-3-20
pubmed:abstractText
Transdermal drug delivery has been applied to various agents in an effort to decrease the frequency of drug administration and improvement of the patients compliance. In the present study, it could be demonstrated that transdermal monotherapy (BIO TSD) with a beta-blocker (20 mg mepindolol) in patients with essential hypertension led to an effective 24 h blood pressure lowering effect within 1 week (160.1 +/- 6.1 mmHg/95.8 +/- 8.3 mmHg vs. 136.8 +/- 7.2 mmHg/84.3 +/- 5.0 mmHg; p less than 0.05). Also a reduction of excessive blood pressure peaks in the circadian blood pressure profiles was observed. Studies comparing transdermal with oral beta-blocker administration in hypertensive patients would further substantiate the value of this new therapeutic system as an antihypertensive treatment.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0004-4172
pubmed:author
pubmed:issnType
Print
pubmed:volume
39
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1512-4
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
Evaluation of the therapeutic effect of transdermal beta-blocker therapy in patients with essential hypertension.
pubmed:affiliation
Medizinische Universitäts-Poliklinik Münster, Fed. Republic of Germany.
pubmed:publicationType
Journal Article